Literature DB >> 28060310

Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation.

Yeri Alice Rim1, Yoojun Nam1, Ji Hyeon Ju2.   

Abstract

The recent development of human induced pluripotent stem cells (hiPSCs) proved that mature somatic cells can return to an undifferentiated, pluripotent state. Now, reprogramming is done with various types of adult somatic cells: keratinocytes, urine cells, fibroblasts, etc. Early experiments were usually done with dermal fibroblasts. However, this required an invasive surgical procedure to obtain fibroblasts from the patients. Therefore, suspension cells, such as blood and urine cells, were considered ideal for reprogramming because of the convenience of obtaining the primary cells. Here, we report an efficient protocol for iPSC generation from peripheral blood mononuclear cells (PBMCs). By plating the transduced PBMCs serially to a new, matrix-coated plate using centrifugation, this protocol can easily provide iPSC colonies. This method is also applicable to umbilical cord blood mononuclear cells (CBMCs). This study presents a simple and efficient protocol for the reprogramming of PBMCs and CBMCs.

Entities:  

Mesh:

Year:  2016        PMID: 28060310      PMCID: PMC5226439          DOI: 10.3791/54650

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  10 in total

Review 1.  Methods of induced pluripotent stem cells for clinical application.

Authors:  Tomohisa Seki; Keiichi Fukuda
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

2.  Reprogramming of T cells from human peripheral blood.

Authors:  Yuin-Han Loh; Odelya Hartung; Hu Li; Chunguang Guo; Julie M Sahalie; Philip D Manos; Achia Urbach; Garrett C Heffner; Marica Grskovic; Francois Vigneault; M William Lensch; In-Hyun Park; Suneet Agarwal; George M Church; James J Collins; Stefan Irion; George Q Daley
Journal:  Cell Stem Cell       Date:  2010-07-02       Impact factor: 24.633

3.  Generation of human iPSCs from human peripheral blood mononuclear cells using non-integrative Sendai virus in chemically defined conditions.

Authors:  Jared M Churko; Paul W Burridge; Joseph C Wu
Journal:  Methods Mol Biol       Date:  2013

4.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

Review 5.  Process engineering of human pluripotent stem cells for clinical application.

Authors:  Margarida Serra; Catarina Brito; Cláudia Correia; Paula M Alves
Journal:  Trends Biotechnol       Date:  2012-04-26       Impact factor: 19.536

6.  Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells.

Authors:  G R Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

7.  Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells.

Authors:  Shin-Ichi Mae; Akemi Shono; Fumihiko Shiota; Tetsuhiko Yasuno; Masatoshi Kajiwara; Nanaka Gotoda-Nishimura; Sayaka Arai; Aiko Sato-Otubo; Taro Toyoda; Kazutoshi Takahashi; Naoki Nakayama; Chad A Cowan; Takashi Aoi; Seishi Ogawa; Andrew P McMahon; Shinya Yamanaka; Kenji Osafune
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

9.  Induced pluripotent stem cells and personalized medicine: current progress and future perspectives.

Authors:  Yong Soon Chun; Kyunghee Byun; Bonghee Lee
Journal:  Anat Cell Biol       Date:  2011-12-30

10.  Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells.

Authors:  Seiga Ohmine; Allan B Dietz; Michael C Deeds; Katherine A Hartjes; David R Miller; Tayaramma Thatava; Toshie Sakuma; Yogish C Kudva; Yasuhiro Ikeda
Journal:  Stem Cell Res Ther       Date:  2011-11-16       Impact factor: 6.832

  10 in total
  7 in total

1.  Chondrogenic Pellet Formation from Cord Blood-derived Induced Pluripotent Stem Cells.

Authors:  Yoojun Nam; Yeri Alice Rim; Ji Hyeon Ju
Journal:  J Vis Exp       Date:  2017-06-19       Impact factor: 1.355

2.  Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models.

Authors:  Sarah Logan; Thiago Arzua; Scott G Canfield; Emily R Seminary; Samantha L Sison; Allison D Ebert; Xiaowen Bai
Journal:  Compr Physiol       Date:  2019-03-14       Impact factor: 9.090

3.  Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis.

Authors:  Yena Kim; Yoojun Nam; Yeri Alice Rim; Ji Hyeon Ju
Journal:  Stem Cell Res Ther       Date:  2022-07-15       Impact factor: 8.079

4.  Different Chondrogenic Potential among Human Induced Pluripotent Stem Cells from Diverse Origin Primary Cells.

Authors:  Yeri Alice Rim; Yoojun Nam; Narae Park; Hyerin Jung; Yeonsue Jang; Jennifer Lee; Ji Hyeon Ju
Journal:  Stem Cells Int       Date:  2018-01-21       Impact factor: 5.443

5.  Preferential stimulation of melanocytes by M2 macrophages to produce melanin through vascular endothelial growth factor.

Authors:  Heeju Han; Yena Kim; Hyunkyung Mo; Si Hwa Choi; Kijun Lee; Yeri Alice Rim; Ji Hyeon Ju
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

Review 6.  Current Therapeutic Strategies for Stem Cell-Based Cartilage Regeneration.

Authors:  Yoojun Nam; Yeri Alice Rim; Jennifer Lee; Ji Hyeon Ju
Journal:  Stem Cells Int       Date:  2018-03-25       Impact factor: 5.443

Review 7.  Contribution of Human Pluripotent Stem Cell-Based Models to Drug Discovery for Neurological Disorders.

Authors:  Alexandra Benchoua; Marie Lasbareilles; Johana Tournois
Journal:  Cells       Date:  2021-11-24       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.